European Journal of Cancer最新文献

{"title":"Clinical evaluation of the role of miRNA 371 in small testicular masses. Results of the “S1STeM 371” Trial","authors":"Sebastiano Nazzani ,&nbsp;Adele Busico ,&nbsp;Valentina Bernasconi ,&nbsp;Martina Bruniera ,&nbsp;Martina Gianninò ,&nbsp;Daniele Rusconi ,&nbsp;Jessica Gualtieri ,&nbsp;Carlo Silvani ,&nbsp;Alberto Macchi ,&nbsp;Tullio Torelli ,&nbsp;Silvia Stagni ,&nbsp;Antonio Tesone ,&nbsp;Cesare Saitta ,&nbsp;Iolanda Capone ,&nbsp;Tommaso Cascella ,&nbsp;Rodolfo Lanocita ,&nbsp;Marco Barella ,&nbsp;Biagio Paolini ,&nbsp;Federica Perrone ,&nbsp;Giancarlo Albo ,&nbsp;Nicola Nicolai","doi":"10.1016/j.ejca.2025.115494","DOIUrl":"10.1016/j.ejca.2025.115494","url":null,"abstract":"<div><h3>Aim of the study</h3><div>Incidental small testicular masses (STMs) pose the dilemma of invasive Vs surveillance. To test miRNA 371 kit (M371, CE approved) in predicting germ cells tumor (GCT) in patients with STM.</div></div><div><h3>Methods</h3><div>Thirty-two consecutive men with a STM between 5 and 20 mm have been prospectively accrued. All patients had miRNA 371 blood testing before surgery. Serum miRNA processation was standardized and certified and following transcription into cDNA with an endogeneous control. The Relative Quantity (RQ) was determined by quantitative polymerase chain reaction (qPCR) following preamplification. Different RQ cut-offs were tested. The results of pre-surgery 371 miRNA were compared to definitive pathology.</div></div><div><h3>Results</h3><div>Median lesion size was 14 mm (IQR 8–18 mm). 21 of 32 patients (65.6 %) had GCTs: 14 seminomatous (S)GCTs, 6 non-seminomatous (NS)GCTs, 1 in-situ germ cell neoplasia (GCNIS). Median RQ was 57.50 (IQR 18.50, 223.75) among GCT patients and 5.00 (IQR 1.00, 13.50) in patients without GCTs. We tested for sensitivity (SE), specificity (SP), positive (PPV) and negative predictive value (NPV) at different RQ cut-offs of 5 and 10. SE, SP, PPV and NPV were 100 %, 45 %, 78.1 %, 100 % 95.2 %, 63.7 %, 83.6 %, 87.3 %, respectively.</div></div><div><h3>Conclusions</h3><div>Serum miRNA 371 can predict GCTs in selected patients with 5–20 mm STM. These results need to be refined by standardizing the analytical process.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"223 ","pages":"Article 115494"},"PeriodicalIF":7.6,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144071463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations","authors":"Marie Morfouace ,&nbsp;Franck Bielle ,&nbsp;Evangelia Razis ,&nbsp;Florian Estrade ,&nbsp;Alba Rubio ,&nbsp;Francisco Bautista ,&nbsp;Teresa de Rojas ,&nbsp;Maria Vieito ,&nbsp;Sara Meade ,&nbsp;Marc Sanson ,&nbsp;Andreia Capela Marques ,&nbsp;Matthias Preusser ,&nbsp;Helen Hatcher ,&nbsp;Gnana Prakash Balasubramanian ,&nbsp;Estela Pineda ,&nbsp;Lionel D’Hondt ,&nbsp;Johnny Duerinck ,&nbsp;Alex Michotte ,&nbsp;Christian Mawrin ,&nbsp;Teresa Ribalta ,&nbsp;Martin G. McCabe","doi":"10.1016/j.ejca.2025.115493","DOIUrl":"10.1016/j.ejca.2025.115493","url":null,"abstract":"<div><h3>Background</h3><div>Adolescent and young adult (AYA) high grade gliomas (HGG) have the worst survival of AYA malignancies yet are poorly represented in large-scale molecular datasets.</div></div><div><h3>Methods</h3><div>50 AYAs aged 12–29 with newly diagnosed or recurrent HGG and other high risk central nervous system (CNS) tumours were prospectively recruited to the EORTC SPECTA platform study and underwent whole exome sequencing, RNA sequencing and methylation profiling, with central pathological review. Actionable mutations were reported and patients followed up for therapies and outcome.</div></div><div><h3>Results</h3><div>From 46 locally diagnosed HGGs and 4 other recurrent CNS tumours, molecular and pathology review resulted in histological grade re-classification (n = 10), diagnostic refinement (n = 9) and revised diagnoses (n = 12) in a substantial proportion. Pathogenic constitutional alterations were present in 14 % overall and were largely limited to cases with IDH-wildtype glioblastoma and paediatric-type diffuse HGGs. 91 % of HGGs had potentially actionable alterations affecting RAS/RAF/MAPK (60 %), PI3K/AKT/mTOR (27 %) and cell cycle genes (11 %). High tumour mutational burden (&gt; 10 somatic non-synonymous mutations per Mb of genome targeted) was present in 12 % at diagnosis and 18 % at recurrence, all in histological grade 4 tumours. Ten patients’ treatment was modified on the basis of molecular profile, of whom 5 remained on treatment at last follow-up.</div></div><div><h3>Conclusion</h3><div>AYA HGGs comprise a diverse group of entities; accurate, molecularly-defined diagnosis is critical to direct primary treatment, determine risk of genetic predisposition and guide molecularly-directed therapy. Current services fail to routinely address diagnosis, personalised molecular profiling or investigation of therapeutic opportunities for this high risk, poor prognosis group of rare cancer patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"223 ","pages":"Article 115493"},"PeriodicalIF":7.6,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial","authors":"Chiara Dauccia ,&nbsp;Maria Alice Franzoi ,&nbsp;Samuel Martel ,&nbsp;Dominique Agbor-Tarh ,&nbsp;Shona Fielding ,&nbsp;Martine Piccart ,&nbsp;Jose Bines ,&nbsp;Sibylle Loibl ,&nbsp;Serena Di Cosimo ,&nbsp;Ines Vaz-Luis ,&nbsp;Antonio Di Meglio ,&nbsp;Lucia Del Mastro ,&nbsp;Andrea Gombos ,&nbsp;Christine Desmedt ,&nbsp;Guy Jerusalem ,&nbsp;Linda Reaby ,&nbsp;Tadeus Pienkowski ,&nbsp;Matteo Lambertini ,&nbsp;Elisa Agostinetto ,&nbsp;Evandro de Azambuja","doi":"10.1016/j.ejca.2025.115489","DOIUrl":"10.1016/j.ejca.2025.115489","url":null,"abstract":"<div><h3>Background</h3><div>Body mass index (BMI) may affect prognosis in patients with breast cancer (BC). We assessed the association of BMI and weight changes with outcomes of patients with HER2-positive early BC included in the APHINITY trial.</div></div><div><h3>Methods</h3><div>This is an exploratory analysis of APHINITY (NCT01358877), randomized trial testing adjuvant dual vs. single HER2 blockade plus chemotherapy in HER2-positive early BC. BMI was collected at baseline and at two years after randomization. Patients were classified as underweight/normal weight (BMI&lt;25 kg/m²) and overweight/obese (BMI≥25 kg/m²). The association of BMI with invasive disease-free survival (iDFS), distant recurrence-free interval (DRFI) and overall survival (OS) was investigated. Landmark approach was used to compare event for weight change ≥ 5.0 % at 2 years from baseline.</div></div><div><h3>Results</h3><div>Of 4787 patients included, 2252 (47 %) were overweight/obese and 2535 (53 %) underweight/normal weight. Patients who were overweight/obese had more often chemotherapy discontinuation compared to underweight/normal weight patients (14 % vs. 9 %, p &lt; 0.001). Patients who were overweight/obese exhibited worse iDFS (adjusted hazard ratio [aHR] 1.27; 95 % CI 1.06–1.52), DFRI (aHR 1.32; 95 % CI 1.06–1.64) and OS (aHR 1.38; 95 %CI 1.08–1.77) than underweight/normal weight patients. This effect on iDFS remained after adjusting for chemotherapy discontinuation (iDFS aHR 1.26, 95 % CI 1.05–1.51; DRFI aHR 1.31, 95 % CI 1.06–1.63; OS aHR 1.35 95 % CI 1.05–1.73). Weight changes at 2 years were not associated with clinical outcomes.</div></div><div><h3>Conclusions</h3><div>Our exploratory findings suggest that overweight/obesity at diagnosis was associated with worse survival outcomes.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"223 ","pages":"Article 115489"},"PeriodicalIF":7.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143941414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma","authors":"Robert L. Hollis,&nbsp;C. Simon Herrington,&nbsp;Charlie Gourley","doi":"10.1016/j.ejca.2025.115491","DOIUrl":"10.1016/j.ejca.2025.115491","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115491"},"PeriodicalIF":7.6,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high-grade serous carcinoma","authors":"Berkan Karabuga ,&nbsp;Kadriye Baskurt ,&nbsp;Nurlan Mammadzada ,&nbsp;Osman Sutcuoglu","doi":"10.1016/j.ejca.2025.115490","DOIUrl":"10.1016/j.ejca.2025.115490","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115490"},"PeriodicalIF":7.6,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”","authors":"Rudolf Stadler ,&nbsp;Gabriele Roccuzzo ,&nbsp;Pablo Ortiz-Romero ,&nbsp;Martine Bagot ,&nbsp;Pietro Quaglino ,&nbsp;Emmanuella Guenova ,&nbsp;Constanze Jonak ,&nbsp;Evangelia Papadavid ,&nbsp;René Stranzenbach ,&nbsp;Sandrine Marreaud ,&nbsp;Jammbe Musoro ,&nbsp;Jose Casas-Martin ,&nbsp;Duncan Murray ,&nbsp;Samantha Drennan ,&nbsp;Jimmy Van Hear ,&nbsp;Paul Moss ,&nbsp;Delphine Sartori ,&nbsp;Maxime Battistella ,&nbsp;Rein Willemze ,&nbsp;Julia Scarisbrick ,&nbsp;Robert Knobler","doi":"10.1016/j.ejca.2025.115484","DOIUrl":"10.1016/j.ejca.2025.115484","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatment of advanced mycosis fungoides (MF) and Sézary syndrome (SS) is a challenge. In this international, multicenter, open-label phase II trial, we assessed the efficacy and safety of anti-PD-L1 atezolizumab in stage IIB-IV refractory/relapsed MF and SS.</div></div><div><h3>Materials and methods</h3><div>Patients received atezolizumab 1200 mg IV Q3w for up to 1 year unless progression or withdrawal. The main study endpoints were overall response rate (ORR), progression-free survival (PFS), time to next systemic treatment (TTNT), and overall survival (OS).</div></div><div><h3>Results</h3><div>A total of 26 patients were enrolled from seven countries. Seventeen patients met the inclusion criteria. At a median follow-up of 36.6 months, the ORR was 15.4 % in the intention to treat (ITT) and 17.6 % in the per protocol (PP) population, respectively. In the PP group, 58.8 % of patients, and in the ITT group, 53.9 % of patients achieved partial response or stable disease as their best outcome. One complete response was observed after 1 year. Median PFS was 3 months (95 % CI 1.4–4.9) in PP and 3.1 months (95 % CI 2.4–4.0) in ITT. Median OS was not reached for PP and was 22.3 months (20.0-NE) for ITT. Median TTNT was 5.9 months (2.8-NE) in PP and 6.2 months (3.1–14.8) in ITT. The most common grade ≥ 3 adverse events were fatigue (23.1 %) and infections (15.4 %), with two sepsis-related deaths. Atezolizumab was primarily discontinued due to disease progression (50 %).</div></div><div><h3>Conclusions</h3><div>Atezolizumab shows moderate activity in pretreated refractory/relapsed MF and SS. Further studies are needed to identify reliable predictors of safety and treatment response.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115484"},"PeriodicalIF":7.6,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.","authors":"S Ganame, T Walter, A Durand, A Lièvre, D Tougeron, J-Y Scoazec, E Baudin, C Lepage, O Boussari, J Hadoux","doi":"10.1016/j.ejca.2025.115450","DOIUrl":"https://doi.org/10.1016/j.ejca.2025.115450","url":null,"abstract":"<p><strong>Aim: </strong>Randomized trials are very challenging to perform in rare cancers such as gastro-enteropancreatic neuroendocrine carcinomas. We hypothesized that the randomized BEVANEC trial of FOLFIRI + /- bevacizumab could have been designed with an external control arm (ECA) and led to similar results.</p><p><strong>Methods: </strong>For this proof of concept, BEVANEC-EMU was emulated as a prospective single experimental arm (EA) trial of FOLFIRI + bevacizumab (BEVANEC data) vs an ECA of FOLFIRI from real world data (RWD) with similar inclusion criteria and primary endpoints.</p><p><strong>Results: </strong>RWD characteristics were similar to those of BEVANEC. Missing data were observed for some patients in RWD (LDH, PAL and performance status). After weighting by the inverse of propensity-score, patient's characteristics were as well balanced between the ECA -n = 66) and the EA of BEVANEC-EMU (n = 59) as between the 2 randomized arm of BEVANEC trial. The 6-months OS rates were 61.1 % [95 %CI 48.9;76.5] in the EA and 53.4 % [95 %CI 42.2;67.6] in the ECA. In BEVANEC-EMU, the primary endpoint was met in both arms, as observed in the BEVANEC trial. The same conclusions were drawn when a hybrid ECA (generated by a mixture of RWD and prospective data from BEVANEC). A custom randomization algorithm which incrementally incorporate RWD into a prospective comparative externally controlled trial is described.</p><p><strong>Conclusions: </strong>The BEVANEC trial could have been led as an externally-controlled trial. This proof of concept led to the design of REWENEC-01, a funded prospective comparative externally-controlled trial for the evaluation of an immunotherapy combination in association with FOLFIRI in GEP NEC patients.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":" ","pages":"115450"},"PeriodicalIF":7.6,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis","authors":"Chris Labaki ,&nbsp;Marc Eid ,&nbsp;Ziad Bakouny ,&nbsp;Charbel Hobeika ,&nbsp;Razane El Hajj Chehade ,&nbsp;Roy Chebel ,&nbsp;Stergios Boussios ,&nbsp;F. Anthony Greco ,&nbsp;Nicholas Pavlidis ,&nbsp;Elie Rassy","doi":"10.1016/j.ejca.2025.115447","DOIUrl":"10.1016/j.ejca.2025.115447","url":null,"abstract":"<div><h3>Background</h3><div>Cancers of unknown primary (CUP) are associated with a high mortality rate, with limited therapeutic options available and platinum-based chemotherapy recommended as standard of care. Over the past decade, molecularly guided approaches aiming to adapt treatment strategies in patients with CUP based on predicted site of origin (site-specific approach) or genomic characteristics (tissue-agnostic approach) have been explored in clinical studies, with heterogenous findings identified.</div></div><div><h3>Methods</h3><div>PubMed/MEDLINE, Scopus, Web of Science, Embase, the Cochrane Library, and conference abstracts of American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) meetings were searched from inception until October 2024, for clinical studies that assessed molecularly directed therapies (MDT) in the management of patients with CUP, as compared to empiric treatment. A meta-analysis using a random-effects model and the inverse variance method was conducted, with a subgroup analysis by study design (randomized versus non-randomized). The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS).</div></div><div><h3>Results</h3><div>Six studies encompassing 1644 patients were included, of which 4 randomized controlled trials. A significant improvement of OS in patients with CUP treated with MDT versus empiric therapy was identified (HR: 0.75, 95 %CI: 0.62–0.91), with consistent results seen across randomized (HR: 0.86, 95 %CI: 0.73–1.01) and non-randomized (HR: 0.50, 95 %CI: 0.26–0.96). Similarly, PFS was significantly improved with MDT, as compared to empiric treatment (HR: 0.79, 95 %CI: 0.67–0.94).</div></div><div><h3>Conclusion</h3><div>The use of MDT is associated with improved survival outcomes among patients with CUP. These findings provide evidence that support the role of MDT as a potential novel standard of care in CUP treatment.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115447"},"PeriodicalIF":7.6,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143898690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study","authors":"Marco Fiore ,&nbsp;Silva Ljevar ,&nbsp;Chandraijt Premanand Raut ,&nbsp;Giulia Personeni ,&nbsp;Mikhael Rabih ,&nbsp;Rebecca Gladdy ,&nbsp;Kelly Mercier ,&nbsp;Megan Sulciner ,&nbsp;Enrica Rossi ,&nbsp;Dimitri Tzanis ,&nbsp;Harini Suraweera ,&nbsp;Chiara Colombo ,&nbsp;Marianna Coppola ,&nbsp;Sylvie Bonvalot ,&nbsp;Sara Iadecola ,&nbsp;Catherine Sarre-Lazcano ,&nbsp;Costanza Figura ,&nbsp;Daniela Salvatore ,&nbsp;Rosalba Miceli ,&nbsp;Alessandro Gronchi","doi":"10.1016/j.ejca.2025.115474","DOIUrl":"10.1016/j.ejca.2025.115474","url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate desmoid fibromatosis (DF) progression and obstetric outcomes during and after pregnancy, providing evidence to inform clinical decision-making and counseling.</div></div><div><h3>Methods</h3><div>This international, multicenter, retrospective observational study included data from 157 women with DF, contributing 177 pregnancies. Women were classified into three groups: DF diagnosed during pregnancy (Group A), pregnancy occurring after the diagnosis of DF (Group B: DF in situ during pregnancy), or pregnancy in previously resected DF (Group C). Logistic regression and tumor size trend analyses were conducted.</div></div><div><h3>Results</h3><div>Among 177 pregnancies, Group A exhibited the highest rates of DF progression (68.7 % during pregnancy, 40.6 % postpartum), while Groups B and C had lower progression rates (9.5 % during pregnancy, 8.3 % postpartum). Active treatment was required in 5.6 % of cases. Spontaneous regression occurred in 23.7 % of pregnancies, particularly following progression. Obstetric complications were comparable to those in the general population.</div></div><div><h3>Conclusion</h3><div>Pregnancy is generally safe for women with DF, particularly after prolonged disease stability. Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115474"},"PeriodicalIF":7.6,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143905992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant treatment of gastrointestinal stromal tumor: State of the art in 2025","authors":"Nicolas Penel ,&nbsp;Axel Le Cesne ,&nbsp;Jean-Yves Blay","doi":"10.1016/j.ejca.2025.115473","DOIUrl":"10.1016/j.ejca.2025.115473","url":null,"abstract":"<div><div>The management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the discovery of their sensitivity to imatinib. Most localized GISTs can be cured by surgery alone. The present overview aims to discuss the results of four recent randomized trials or updates assessing adjuvant imatinib. The duration of adjuvant treatments varied in these 4 trials (1 year <em>versus</em> zero, 2 years <em>versus</em> zero, 3 years <em>versus</em> 1 year and 6 years <em>versus</em> 3 years). All these trials showed that adjuvant imatinib improves disease/relapse-free survival in patients at high-risk of GIST relapse. Nevertheless, only one trial showed an overall survival improvement, in favor of 3-year treatment compared to 1-year treatment. But these randomized trials did not assess <em>KIT</em> or <em>PDGFRA</em> mutational status at study entry. Moreover, the definition of high-risk GIST differed across these trials. So, the patient subset that benefits the most from adjuvant imatinib therapy remains undetermined. The optimal duration of adjuvant imatinib therapy remain unclear.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115473"},"PeriodicalIF":7.6,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143888202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}